Regeneron antibody cuts risk of COVID-19 death in UK study

Bio Pharma Dive

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients

Who would get Regeneron's COVID-19 antibody treatment?

Bio Pharma Dive

Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention

Bio Pharma Dive

The expanded authorization comes amid surging demand for antibody treatments, particularly in states with lower rates of coronavirus vaccination

Versant partners with AbCellera to arm startups with better antibodies

Bio Pharma Dive

The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact

Antibody shows promise for developing hantavirus treatment

Scienmag

An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar. Biology antibody developing hantavirus promise shows treatment

FDA clears Lilly's COVID-19 antibody cocktail for emergency use

Bio Pharma Dive

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death

UTMB study shows common antibody therapy has anti-SARS-CoV-2 Antibodies

Scienmag

GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. Latest News Antibodies antibody antiSARSCoV2 common shows study therapy UTMB

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Scienmag

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).

How a COVID-19 infection spurs antibodies against common colds

Scienmag

LA JOLLA, CA—Getting sick with a common cold doesn’t make you immune to COVID-19, but a COVID-19 infection might, at least temporarily, boost the number of antibodies you have against common cold-causing coronaviruses and the SARS-CoV-1 and MERS-CoV viruses, all of which are closely related.

Breakthrough COVID-19 infections spur strong antibody responses

Scienmag

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2. Medicine & Health antibody breakthrough COVID19 infections responses spur strong

Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody

Bio Pharma Dive

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.

Scientists analyze structure of antibodies that could be key to more effective cancer treatments

Scienmag

Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer. The findings have enabled the Southampton team to design antibodies to […].

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

F.D.A. Authorizes Another Antibody Treatment

NY Times

internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.

A startup raises $336M to make a better antibody drug for COVID-19

Bio Pharma Dive

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests

Scripps Research scientists explain what makes COVID-19 antibody “J08” so potent

Scienmag

LA JOLLA, CA—Last year, scientists at Scripps Research and Toscana Life Sciences studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus. Medicine & Health antibody COVID19 explain J08 potent research scientists Scripps

US buys up supply of new Lilly antibody meant to work versus omicron

Bio Pharma Dive

Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday

US stops rollout of Lilly's first COVID-19 antibody over variant concerns

Bio Pharma Dive

Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials

AstraZeneca antibody cleared by FDA for preventive use against COVID-19

Bio Pharma Dive

Evusheld, a combination of two antibodies, is meant to be long-acting, proving protective against disease through six months in clinical testing

Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

Bio Pharma Dive

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech

J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies

Bio Pharma Dive

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors

New antibody detection method for coronavirus that does not require a blood sample

Scienmag

Now, investigators from Japan have developed a new antibody-based method for the rapid and reliable detection of SARS-CoV-2 […]. Medicine & Health antibody blood coronavirus detection method require sample

Antibody with engineered peptide targets bone metastasis

Scienmag

Cancer antibody bone Engineered metastasis peptide targetsHOUSTON – (Jan. 24, 2022) – A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

F.D.A. Clears Monoclonal Antibody Drug From Eli Lilly

NY Times

The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness. Eli Lilly and Company Antibodies Food and Drug Administration Coronavirus Omicron Variant Drugs (Pharmaceuticals) Coronavirus (2019-nCoV

Antibody Drug to Protect the Vulnerable From Covid Goes Unused

NY Times

Shortages AstraZeneca PLC Immune System Antibodies Coronavirus (2019-nCoV) Chronic Condition (Health) Drugs (Pharmaceuticals) Transplants United States Politics and Government

Sanofi pays IGM $150M, continuing search for better antibody drugs

Bio Pharma Dive

The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines

US pauses distribution of Regeneron, Lilly antibodies over omicron concerns

Bio Pharma Dive

The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread

Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push

Bio Pharma Dive

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround

New COVID-19 nasal spray outperforms current antibody treatments in mice

Scienmag

Medicine & Health antibody COVID19 current mice nasal outperforms spray treatmentsA new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St.

Mayo Clinic researchers develop new antibody test to diagnose MS

Scienmag

Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. Latest News antibody Clinic develop diagnose Mayo researchers testROCHESTER, Minn. Nearly 1 million people in the U.S. are affected by MS, according to the National Multiple Sclerosis Society.

AstraZeneca buys into startup RQ Bio’s COVID antibodies

Pharma Phorum

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19.

Behind the made-in-Canada approach to tracking COVID-19 antibodies

Scienmag

Technology and Engineering Antibodies approach COVID19 madeinCanada trackingWith every quiet pass of the robotic arm in a research lab at the Lunenfeld-Tanenbaum Research Institute (LTRI) in downtown Toronto, more questions about COVID-19 are being answered.

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention

Pharma Phorum

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections. The post CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention appeared first on.

COVID-19 neutralising antibody tests – an integrated approach

Pharma Phorum

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies.

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

Bio Pharma Dive

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.

IgG antibodies in breast milk help shape infants’ gut bacteria and immunity

Scienmag

Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies. Now a new preclinical study by Weill Cornell Medicine investigators shows that one specific set of antibodies that is induced […]. Latest News Antibodies Bacteria breast gut IgG immunity infants milk shape

Antibody function antibody dependent cellular cytotoxicity (ADCC) may help prevent the transmission of HIV from mother to child during breastfeeding

Scienmag

BOSTON – According to new research from Boston Medical Center, the antibody function known as antibody dependent cellular cytotoxicity (ADCC) and the ADCC sensitivity of HIV strains may influence the transmission of HIV from mother to child during breastfeeding. Latest News ADCC antibody breastfeeding cellular child cytotoxicity dependent function HIV mother prevent transmission

Regeneron enlists Roche to boost production of COVID-19 antibody drug

Bio Pharma Dive

Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own

Unexpected antibody type found in people with malaria infections

Scienmag

However, in a newly published study, researchers at the University of Maryland School of Medicine (UMSOM) have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as […].

In multiple myeloma, cell therapies lead but antibody drugs could follow fast

Bio Pharma Dive

But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.

Model shows how antibodies navigate pathogen surfaces like a child at play

Scienmag

A new study shows how antibodies select the antigens that they bind to, as they navigate the surface of pathogens like coronaviruses. Medicine & Health Antibodies child model navigate pathogen play shows surfaces

Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug

Bio Pharma Dive

The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use